Companies
From start-ups to market leaders, access critical company intelligence on a global scale
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
The G/GEJAC pipeline is highly active and evolving; it features 330 products across all stages of clinical development, with monoclonal antibodies prominently featured in Phase III.
Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer, and the third most common cause of cancer death in the world. This report is part of our Biosimilars market series.
53% of G/GEJAC clinical trials are located in the Asia-Pacific region, with 43% in Japan. The APAC region shows to be a considerable global lead in clinical activity, followed by North America.
Other key findings from this report include the approval of PD-(L)1 modulators is expected to transform the market in future.
As there are no screening programs for these cancers in most of the 8MM (with the exception of Japan) most cases of G/GEJAC are diagnosed at advanced stage, which has poor prognoses. The current G/GEJAC treatment landscape is still very dependent on chemotherapy.
Our Biosimilars market report provides an assessment of the pipeline, clinical, and commercial landscape. Stay ahead of the curve by getting a thorough understanding of the market.